Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
Feature|Videos|March 30, 2026
Your Patient's New Therapist Is an AI. Now What?
Fact checked by: Chelsie Derman
As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.
Advertisement
Advertisement
Watch the full expert dynamic feature above.
Related to this article
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Advertisement
Advertisement